▶주메뉴 바로가기
▶본문 바로가기
SK Biopharmaceuticals said Wednesday it is accelerating its expansion into Latin America by launching its epilepsy treatment Cenobamate in Brazil, as the firm's CEO joined South Korean President Lee Jae Myung's economic delegation for the first time. The only representative from Korea's pharmaceutical and biotechnology industry to participate in the presidential economic delegation to Brazil, SK Biopharmaceuticals signed a memorandum of understanding with Eurofarma, a local pharmaceutical powerh
Celltrion has turned in yet another record quarterly earnings report on growing sales of its newer biosimilar portfolio and improving manufacturing efficiency. According to the Korean biopharmaceutical company on Monday, it logged 1.4 trillion won ($950 million) in sales and 451.8 billion won in operating profit in the April to June period, up 45 percent and 86.3 percent, respectively, from the same period in 2025. The company previously posted record-setting sales of 1.145 trillion won and an o
HLB Pep said Monday that it has registered its vasopressin active pharmaceutical ingredient with the US Food and Drug Administration’s Drug Master File system, advancing its push into global peptide drug markets. Vasopressin is used to treat septic shock and severe hypotension. A DMF is a confidential submission detailing an ingredient’s manufacturing process, quality controls and stability, which drugmakers can reference in regulatory applications. The US registration follows HLB Pep’s registra
Lee Moon Won Bio said Monday it has been selected for TIPS, South Korea’s flagship government-backed program for promising technology startups. The research company was founded on two decades of clinical experience at Lee Moon Won Korean Medicine Clinic. Its intellectual property portfolio includes 11 patents and applications filed under the international Patent Cooperation Treaty. Under the program, Lee Moon Won Bio will receive about 800 million won ($545,200) in government research funding ov
EuBiologics said Friday it has completed registration of its proprietary vaccine adjuvant EcML with the US Food and Drug Administration's Drug Master File system, obtaining an official filing number that is expected to facilitate future vaccine development and licensing partnerships. The registration contains key chemistry, manufacturing and controls, or CMC, data, including information on EcML's raw materials, manufacturing process and quality specifications. EuBiologics said the filing allows
Hugel has officially launched its botulinum toxin brand Letybo in India, seeking to establish an early foothold in one of the world's fastest-growing aesthetics markets. The Korean medical aesthetics company said Wednesday that it introduced Letybo during the Global Aesthetics Summit held July 19-21 in Goa, marking the product's official commercial debut in India. At the conference, Hugel partnered with local distributor Aakaar Medical to raise brand awareness and strengthen relationships with k
Seegene said Tuesday that its US subsidiary has received emergency use authorization from the US Food and Drug Administration for a molecular diagnostic test that can simultaneously detect four viruses associated with similar skin and mucosal lesions. The Allplex HSV-1&2/VZV/MPXV Assay is a syndromic real-time polymerase chain reaction test developed by Seegene USA. It detects herpes simplex virus types 1 and 2, varicella-zoster virus and the virus that causes mpox in a single test. The company
Samsung Biologics said Monday it has launched a $1.8 billion all-cash bid to acquire 100 percent of PolyPeptide, entering the peptide sector to bolster its multi-modality and global manufacturing capabilities. The transaction is expected to be completed by the end of this year to mark the biggest takeover in the history of Korea’s biopharmaceutical industry, according to the company, which is Korea’s leading contract development and manufacturing organization, or CDMO. As PolyPeptide's shares ar
The Korea Biotechnology Industry Organization (KoreaBIO) called for closer bio supply chain cooperation between South Korea and Taiwan at BIO Asia-Taiwan 2026, highlighting the potential for deeper partnerships in biopharmaceutical manufacturing, digital health and startup investment. At the conference held in Taipei from July 15 to 19, KoreaBIO co-hosted the Korea Session to showcase the country's biotech ecosystem and promote greater open innovation between the two economies. Speaking at the "
HLB said Wednesday it received a Voluntary Action Indicated notice from the US Food and Drug Administration after the American authorities had conducted an on-site inspection of the Chinese production site for liver cancer therapy candidate Rivoceranib, reigniting the hopes of getting the FDA’s greenlight for the anti-cancer treatment. HLB's US subsidiary Elevar Therapeutics received a close-out letter from the FDA regarding the current Good Manufacturing Practice, or cGMP, inspection at its par
Chipotle bets on Korea for first bite of Asia
Samsung vs. LG battle for AI cooling heats up
Musinsa posts record earnings on offline, global expansion
One purchase every 0.9 second: Olive Young foreign sales top W1tr
Samsung, SK hynix tax payments surge 167% on chip boom
SK Chemicals eyes European can-coating market
Sept. 2, 2026
July 29, 2026
July 27, 2026
July 27, 2026
July 27, 2026
July 24, 2026
July 22, 2026
July 21, 2026
July 20, 2026
July 20, 2026
July 15, 2026
